Sort
16,300 grants matching “fatty liver disease”
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs
$664,100David L Thomas · Johns Hopkins University · R01 · FY2021 · DA
Identification and Characterization of Loci Associated with Non-alcoholic Fatty Liver Disease
$664,005Nicholette D. Allred · Wake Forest University Health Sciences · R01 · FY2023 · DK
Association of Genomic Predictors of Body Fat Amount and Distribution and of tti
$663,852Iona C Cheng · University Of Hawaii At Manoa · P01 · FY2013 · CA
Regulation of disease progression by ER stress
$663,730A Brent Carter · University Of Alabama At Birmingham · R01 · FY2025 · HL
Exosomes and insulin action in metabolically healthy and unhealthy obesity
$663,670Samuel Klein · Washington University · R01 · FY2025 · DK
ANGPTL3 DEFICIENCY AND ATHEROSCLEROSIS IN HUMANS
$663,467Nathan Oliver Stitziel · Washington University · R01 · FY2017 · HL
Framingham Heart Study/Fox
$662,936Caroline Fox · National Heart, Lung, And Blood Institute · ZIA · FY2013 · HL
Genetic determinants of Bacteroides vulgatus colonization fitness and host inflammatory responses
$662,892John F Rawls · Duke University · R01 · FY2023 · DK
Global HIV Drug Therapies and Mitochondrial Complications and Mechanisms
$662,825Mariana Gerschenson · University Of Hawaii At Manoa · R01 · FY2008 · AI
Searching the blood metabolome to identify risk biomarkers for biliary tract cancer
$662,352Xiao-Ou Shu · Vanderbilt University Medical Center · U01 · FY2024 · CA
Role of IRF3 in Energy and Glucose Homeostasis
$662,216Evan D Rosen · Beth Israel Deaconess Medical Center · R01 · FY2021 · DK
Carotid plaque characteristics by MRI in AIM-HIGH
$662,212Xue-Qiao Zhao · University Of Washington · R01 · FY2010 · HL
A Dietary Intervention to Improve Glucose Tolerance in Adults with Cystic Fibrosis
$662,204Jessica Alejandra Alvarez · Emory University · R01 · FY2025 · DK
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes
$662,119Jian-Min Yuan · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Development of P2Y Receptor Ligands
$662,094Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)
$662,067D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · DK
Role of IRF3 in Energy and Glucose Homeostasis
$661,923Evan D Rosen · Beth Israel Deaconess Medical Center · R01 · FY2022 · DK
TOPMed Omics of Type 2 Diabetes and Quantitative Traits
$661,878Alisa Knodle Manning · Massachusetts General Hospital · UM1 · FY2025 · DK
Discovery of novel therapeutic targets for NASH through deep phenotyping of human knockouts and mechanistic studies
$661,802Ira A Tabas · Columbia University Health Sciences · R01 · FY2025 · DK
Discovery of novel therapeutic targets for NASH through deep phenotyping of human knockouts and mechanistic studies
$661,802Danish Saleheen · Columbia University Health Sciences · R01 · FY2023 · DK
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma
$661,609Hsian-Rong Tseng · Eximius Diagnostics Corp · R44 · FY2023 · CA
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma
$661,609Hsian-Rong Tseng · Eximius Diagnostics Corp · R44 · FY2025 · CA
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma
$661,609Hsian-Rong Tseng · Eximius Diagnostics Corp · R44 · FY2024 · CA
Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular Vesicles
$661,505Yazhen Zhu · University Of California Los Angeles · R01 · FY2025 · CA
Surgical or Medical Treatment for Pediatric Type 2 Diabetes (ST2OMP)
$661,485Michael A Helmrath · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · DK